SCHEMBL10046482

SCHEMBL10046482

COc1cc(C2C3=C(CC(c4ccccc4)CC3=O)OC3=C2C(=O)CC(c2ccccc2)C3)ccc1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
MAPT P10636 1/20 0.50
ALDH1A1 P00352 3/20 0.46
LMNA P02545 2/20 0.46
HTT P42858 2/20 0.46
GPR174 Q9BXC1 1/20 0.46
PTPN1 P18031 2/20 0.45
CYP19A1 P11511 1/20 0.44
ALOX5 P09917 1/20 0.44
PPARG P37231 1/20 0.44
PPARD Q03181 1/20 0.44
USP2 O75604 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
POLB P06746 1/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10046492 0.90 GAA (0.46) GAAMEN1KMT2AL3MBTL1MAPT
SCHEMBL10046494 0.90 GAA (0.56) GAAMEN1KMT2AL3MBTL1MAPT
SCHEMBL10046477 0.86 ALDH1A1 (0.46) GAAMEN1KMT2AMAPTALDH1A1
SCHEMBL14904060 0.84 GAA (0.51) GAAMEN1KMT2AL3MBTL1MAPT
SCHEMBL10046491 0.81 TSHR (0.41) GAAMEN1KMT2AL3MBTL1MAPT
SCHEMBL10046493 0.81 GAA (0.47) GAAMEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL325499 0.78 GPR174 (0.57) GAAMEN1KMT2AL3MBTL1MAPT
SCHEMBL10046487 0.76 GAA (0.73) GAAMEN1KMT2AL3MBTL1MAPT
SCHEMBL3323563 0.75 GAA (0.57) GAAMEN1KMT2AMAPTALDH1A1
SCHEMBL425310 0.71 CA2 (0.60) GAAMEN1KMT2AL3MBTL1PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8906416-B2 Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders PIERRE FABRE DERMO-COSMETIQUE (FR) 2014-12-09 US disclosed
US-8906416-B2 Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders PIERRE FABRE DERMO-COSMETIQUE (FR) 2014-12-09 US disclosed
US-8906416-B2 Xanthenedione derivatives for the treatment of pigmentation and skin ageing disorders PIERRE FABRE DERMO-COSMETIQUE (FR) 2014-12-09 US disclosed
US-20130108568-A1 XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS PIERRE FABRE DERMO-COSMETIQUE (FR) 2013-05-02 US disclosed
US-20130108568-A1 XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS PIERRE FABRE DERMO-COSMETIQUE (FR) 2013-05-02 US disclosed
US-20130108568-A1 XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS PIERRE FABRE DERMO-COSMETIQUE (FR) 2013-05-02 US disclosed
WO-2012004390-A1 XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS PIERRE FABRE DERMO-COSMETIQUE (FR) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130108568-A1 XANTHENEDIONE DERIVATIVES FOR THE TREATMENT OF PIGMENTATION AND SKIN AGEING DISORDERS ACOX3, CBR3, GALR3 GAA 1289/4885MEN1 2682/4885KMT2A 4312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.